Thomas Hofstaetter holds a PhD in Molecular Biology.

He carried out his international career, especially in Germany, the United States and Japan, within international pharmaceutical  groups (Wyeth, Aventis, etc.) on strategic  positions at the highest level in external growth and business development. Over the past two years, until December 2011, he headed VaxInnate Corporation and is now Board Member of Bionor ASA.

Thomas Hofstaetter has been a director of Onxeo since 31 May 2012. His mandate will expire at the shareholders’ annual general meeting of 2021.